Technology Appraisals Endorsement Process
The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013:
For information, details of the previous arrangement can be found on the following circular:
2014/2015
The following technology appraisals have been endorsed during 2014/15. Information on technology appraisals endorsed in previous years can be found on the homepage.
Fully Endorsed
March 2015
- NICE TA 333 - Axitinib for the treatment of advanced renal cell carcinoma after failure of prior systemic treatment
- NICE TA 331 - Simeprevir in combination with peginterferon alfa and ribavirin for treating genotype 1 or 4 chronic hepatitis C
- NICE TA 331 has now been withdrawn. See NICE Website for further information
- NICE TA 329 - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
February 2015
January 2015
December 2014
- NICE TA 326 - Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196)
- NICE TA 325 - Nalmefene for reducing alcohol consumption in people with alcohol dependence
- NICE TA 324 - Dual-chamber pacemakers for treating symptomatic bradycardia due to sick sinus syndrome without atrioventricular block, (part review of Technology Appraisal 88)
- NICE TA 323 - Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142)
November 2014
October 2014
- NICE TA 322 - Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
- NICE TA 320 - Dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis
August 2014
- NICE TA 319 - Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
- NICE TA 318 - Lubiprostone for treating chronic idiopathic constipation
- NICE TA 317 - Prasugrel with percutaneous coronary intervention for treating acute coronary syndrome (review of TA182)
- NICE TA 316 - Enzalutamide for the treatment of metastatic hormone relapsed prostate cancer previously treated with a docetaxel-containing regimen
July 2014
- NICE TA 315 - Canagliflozin in combination therapy for treating type 2 diabetes
- NICE TA 314 - Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (review of TA95 and TA120)
June 2014
- NICE TA 313 - Ustekinumab for treating active psoriatic arthritis
- NICE TA 312 - Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
May 2014
- NICE TA 311 - Bortezomib for induction therapy in multiple myeloma before high dose chemotherapy and autologous stem cell transplantation
- NICE TA 310 - Afatinib for treating epidermal growth factor receptor mutation positive locally advanced or metastatic non-small cell lung cancer
- NICE TA 309 -Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer
- This guidance has been updated and replaced by TA 402 - Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer, which was endorsed by the DoH in September 2016.
April 2014
- NICE TA 308 - Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
- NICE TA 307 - Aflibercept in combination with irinotecan and fluorouracil-based therapy for the treatment of metastatic colorectal cancer which has progressed following prior oxaplatin-based chemotherapy
Endorsed With Caveats
None
Not Endorsed as Applicable to Northern Ireland
None